HOME >> MEDICINE >> NEWS
Colonoscopy still most effective colorectal cancer screening method

Bethesda, Maryland (Jan. 19, 2005) According to a study published in the Jan. 18 issue of the journal Annals of Internal Medicine, fecal occult blood test (FOBT) performed in-office as part of a digital rectal examination failed to detect potentially cancerous colon growths 95 percent of the time. Furthermore, an at-home FOBT was found to detect cancerous polyps less than 24 percent of the time. The entire study population received follow-up colonoscopies, regardless of whether they received digital FOBT or the at-home stool test.

"This study found in-office FOBT as part of a digital rectal examination to be ineffective, illustrating how important it is for people to speak with their physician to determine which colorectal cancer screening test best fits their needs and risk level," says AGA President Emmet B. Keeffe, MD. "No colorectal cancer screening test is perfect. However, being screened for colorectal cancer using one of the various methods available is a better fate than not being tested at all. An alternative use of FOBT is in concert with periodic flexible sigmoidoscopy of the left portion of the colon, rather than the stool test alone.

"It is generally preferable to undergo colonoscopy, which allows complete evaluation of the colon and also, at the same time, biopsy or removal of most cancers or polyps that are identified. If detected early as precancerous polyps, the majority of colorectal cancers are preventable," comments Keeffe.

Guidelines of multiple agencies and professional societies underscore the importance of screening for all individuals 50 years of age and older. Currently, there are several tests that may be used to screen for colorectal cancer, the second-leading cause of cancer deaths in the United States. Approved tests include colonoscopy, flexible sigmoidoscopy, fecal occult blood test and barium enema. Each screening option has advantages and disadvantages.


'"/>

Contact: Kimberly Wise
kwise@gastro.org
301-941-2620
American Gastroenterological Association
19-Jan-2005


Page: 1

Related medicine news :

1. Colonoscopy most reliable method for detecting colon cancer
2. Colonoscopy far more cost-effective against colon cancer than promising Cox II drugs, study predicts
3. Archival virus still necessitates life-long antiretroviral therapy
4. HIV infection still on the rise
5. New rights to access, but for most transparency is still as clear as mud
6. Tide of new nurses rises but shortages still loom large
7. Teenage smoking still worryingly high: Girls twice as likely as boys to puff away
8. Smallpox vaccine can be diluted and still be effective, expanding supply if needed
9. Beneficiaries with chronic conditions still face high costs under new Medicare drug law
10. Hormone therapy may still offer important health benefits to postmenopausal women
11. APA poll: Most Americans have sought mental health treatment but cost, insurance still barriers

Post Your Comments:
(Date:5/21/2013)... Atlanta, GA (PRWEB) May 21, 2013 ... Care, ScripNet and Procura Management, today announced that ... Award at Catamaran’s client advisory meeting. Conferred ... has partnered with Catamaran to create cutting edge ... This year, Healthcare Solutions was recognized for its ...
(Date:5/21/2013)... May 21, 2013 Two-thirds of patients ... cell lung cancer reported that they engage in at ... use, according to new findings from the National ... Kantar Health . The research will be presented today ... Society for Pharmacoeconomics and Outcomes Research) in New Orleans. ...
(Date:5/21/2013)... 2013 A plastic surgery Internet ... plastic surgery SEO services following an Internet survey. ... name the “Best Plastic Surgery SEO Services”. , ... was predictable. Well-known in the plastic surgery Internet ... than any other selection based on superior client ...
(Date:5/21/2013)... May 21, 2013 It’s nearly summer and ... camp or starting practice for summer or fall sports. ... or sporting activities can begin. , To help parents ... for youth sports or camp physicals at just ... will review a child’s medical history, perform a physical exam ...
(Date:5/21/2013)... Nearly 40 Platinum Supplemental Insurance Sales Representatives and ... Cabos, Mexico, Feb. 23-March 1, 2013, to help renovate Casa ... facility serves meals and provides a social outlet for 45 ... Platinum Vice President, Mike Muench, says that the idea for ... “Platinum got its start selling long-term care insurance ,” ...
Breaking Medicine News(10 mins):Health News:Healthcare Solutions Receives Innovation Award From Catamaran 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2Health News:MedSpring Offers Camp and Sports Physicals For $29 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 3
(Date:5/21/2013)... FREDERICK, Md. , May 21, 2013 /PRNewswire/ ... inexpensive, disposable drug-free consumer electronic devices, announced that ... is presenting today to the FDA,s Medical Advisory ... reclassifying the company,s products for over the counter ... the FDA developed its medical device classification schema," ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
Cached News: